Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351765 | 0.92 | KIF11 (0.77) | KIF11HTTADORA2BMAPK1POLB | |
| SCHEMBL5352815 | 0.87 | KIF11 (0.65) | KIF11ADORA2BPOLBHSD17B10PKM | |
| SCHEMBL5345378 | 0.86 | MAPT (0.66) | KIF11HTTADORA2BMAPK1POLB | |
| SCHEMBL6340753 | 0.85 | PKM (0.77) | KIF11ADORA2BGAAPKM | |
| SCHEMBL10113452 | 0.82 | HTT (0.66) | KIF11HTTADORA2BMAPK1GAA | |
| SCHEMBL5568079 | 0.82 | HTT (0.66) | KIF11HTTADORA2BMAPK1POLB | |
| SCHEMBL16323394 | 0.81 | TSHR (0.70) | HTTGAAPKM | |
| SCHEMBL6348122 | 0.81 | HTT (0.75) | KIF11HTTMAPK1POLBHSD17B10 | |
| SCHEMBL5340534 | 0.80 | KIF11 (0.80) | KIF11ADORA2BMAPK1POLBGAA | |
| SCHEMBL31705192 | 0.80 | KIF11 (0.80) | KIF11ADORA2BMAPK1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215108-A1 | DUAL G9A/GSK-3ß INHIBITORS | UNIVERSITAT DE BARCELONA (ES) | 2025-10-16 | — | — | WO | claimed |
| WO-2025215108-A1 | DUAL G9A/GSK-3ß INHIBITORS | UNIVERSITAT DE BARCELONA (ES) | 2025-10-16 | — | — | WO | disclosed |
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | UCL BUSINESS PLC (GB) | 2018-08-02 | — | — | US | disclosed |
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | UCL BUSINESS PLC (GB) | 2018-08-02 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | ELI LILLY AND COMPANY | 2012-02-23 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007101213-A2 | NOVEL 2-OXO-1,2,3,4-TETRAHYDROPYRIMIDINES, BICYCLIC PYRIMIDINE DIONES AND IMIDAZOLIDINE-2,4-DIONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007101213-A2 | NOVEL 2-OXO-1,2,3,4-TETRAHYDROPYRIMIDINES, BICYCLIC PYRIMIDINE DIONES AND IMIDAZOLIDINE-2,4-DIONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214430-A1 | Selective Inhibitors Of i-NOS For Use Against Viral Infection | NOS2, NOS1, NOS3 | KIF11 4741/4885HTT 3378/4885ADORA2B 2610/4885 |
| US-20120046305-A1 | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISORDERS | TRPA1, TRPV1, TRPV3 | KIF11 2568/4885HTT 1239/4885ADORA2B 97/4885 |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | KIF11 1427/4885HTT 1892/4885ADORA2B 493/4885 |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | KIF11 3117/4885HTT 2044/4885ADORA2B 65/4885 |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | KIF11 1427/4885HTT 1892/4885ADORA2B 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.